The glp-1 obesity home delivery injectables market is projected to grow from USD 2.9 billion in 2026 to USD 11.6 billion by 2036, at a CAGR of 14.9%. Semaglutide will dominate with a 42.0% market share, while chronic obesity will lead the patient type segment with a 54.0% share.